Stryker (SYK) Shows ‘Muscle’ at Investor Day, but Truist Stays Neutral

Core Insights - Stryker Corporation (NYSE:SYK) is recognized as a strong player in the MedTech sector, showcasing its ability to deliver consistent operating leverage and growth [2][3] - The company reported third-quarter revenue of $6.1 billion, reflecting over 10% growth year-over-year, with organic sales increasing by 9.5% [3] - Stryker has a notable 32-year streak of dividend growth, appealing to income investors, with a payout ratio of approximately 43% indicating potential for future dividend increases [4] Financial Performance - For Q3 2025, Stryker's revenue reached $6.1 billion, marking a growth of over 10% compared to the same quarter last year [3] - Organic sales growth was reported at 9.5%, driven by a 9.1% increase in unit volume and a 0.4% rise in prices [3] - The company anticipates organic net sales growth of 9.8% to 10.2% moving forward [3] Investment Perspective - Truist's analyst raised the price target for Stryker to $400 from $392 while maintaining a Hold rating, emphasizing the company's strong position in the MedTech industry [2] - Despite the positive outlook, the firm prefers companies with more consistent revenue growth and faster earnings [2] - The appeal of Stryker as a dividend stock is highlighted by its long history of dividend growth and a reasonable payout ratio [4]